bioAffinity 2025 Q2 Earnings Continued Losses Despite Operational Optimism

bioAffinity Technologies reported its fiscal 2025 Q2 earnings on August 15, 2025, with results that fell short of expectations. The company’s net loss widened to $4.06 million, a 92.4% increase from the $2.11 million loss in the same quarter of the prior year. While EPS losses narrowed slightly to $0.17 from $0.19, the company remains unprofitable for the third consecutive year, underscoring ongoing financial challenges.

Revenue
Total revenue declined significantly by 47.1% year-over-year to $1.27 million in the second quarter of 2025, compared to $2.40 million in the prior year period. The revenue breakdown included patient service fees of $942,067, histology service fees of $308,604, medical director fees of $17,309, and other revenues of $1,503. These figures reflect a continued contraction across core service lines.

Earnings/Net Income
The company reported a net loss of $4.06 million in Q2 2025, a 92.4% increase from the $2.11 million loss in the same period the previous year. Although the loss per share improved marginally to $0.17 from $0.19, the overall performance remains negative, highlighting the company’s ongoing financial strain.

Price Action
Following the earnings release, the stock price of bioAffinity fell sharply. It declined 3.70% on the latest trading day, 8.82% over the past week, and 12.87% month-to-date, reflecting investor pessimism.

Post-Earnings Price Action Review
A strategy of purchasing bioAffinity shares after a revenue increase quarter-over-quarter and holding for 30 days proved disastrous over the past three years, delivering a return of -97.61%. This significantly underperformed the benchmark by 157.54%, with a negative Sharpe ratio of -0.43 and a maximum drawdown of 0%, underscoring the high risk and low return associated with such an approach.

CEO Commentary
Maria Zannes, President and CEO of bioAffinity Technologies, emphasized positive developments in CyPath® Lung, including a 62% year-over-year increase in revenues for the first half of 2025. She attributed this growth to physician adoption and real-world validation of the test's utility. Zannes highlighted the success of the Texas pilot marketing program and outlined plans to expand into the Mid-Atlantic region and the Veterans Administration healthcare system. She also noted a 72% monthly increase in testing in July compared to the previous six-month average, along with a $3.25 million public offering and strategic pricing alignment to private payer reimbursement. The CEO expressed confidence in operational efficiency, global IP expansion, and the potential of the company’s siRNA-based cancer therapy.

Guidance
While no specific revenue or earnings guidance was provided, Zannes indicated a focus on expanding access to CyPath® Lung, improving operational efficiency, and advancing next-generation diagnostics and therapeutics. The company aims to implement commercial strategies in new markets and progress toward pivotal clinical trials, reinforcing long-term confidence in its platforms.

Additional News
In a separate development, Shanghai Daily announced the availability of its online edition for digital subscribers. The subscription model includes access to downloadable PDFs of the newspaper in real time, as well as unlimited access to current and archived stories. Subscribers also receive breaking news alerts and digital newsletters. However, it is important to note that digital subscribers do not receive print editions, and online subscriptions are non-refundable. Packages range from a digital-only 1-month subscription to a combined print-and-digital 12-month plan.